Search Results
Your search for ,WHo matches 20700 pages
Showing 14501 - 14550Extending ASCO’s Influence Globally to Improve Patient Care
On June 27, 2016, Clifford A. Hudis, MD, FACP, FASCO, will begin his tenure as Chief Executive Officer of ASCO, succeeding Allen S. Lichter, MD, FASCO, who presided over the Society and the Conquer Cancer Foundation of ASCO since 2006. Dr. Hudis’ dedication to ASCO dates back more than 25 years...
Pembrolizumab Improves Survival vs Docetaxel in Previously Treated PD-L1–Positive Advanced Non–Small Cell Lung Cancer
As reported in The Lancet by Roy S. Herbst, MD, PhD, of Yale School of Medicine, and colleagues,1 the phase II/III KEYNOTE-010 trial showed that pembrolizumab (Keytruda) significantly improved overall survival vs docetaxel in patients with previously treated programmed cell death ligand 1...
Daratumumab Hits the Mark in Early Relapsed Multiple Myeloma
For relapsed or refractory multiple myeloma, daratumumab (Darzalex), combined with bortezomib (Velcade) and dexamethasone, reduced relapses by 61% in the phase III CASTOR study reported at the 2016 ASCO Annual Meeting.1 “The results are unprecedented in a randomized study comparing a novel...
ASCO 2016: Pembrolizumab Shows Significant Clinical Response in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Treating head and neck cancer patients with recurrent or metastatic disease with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) achieved significant clinical responses in nearly one-fifth of the patients from a phase II clinical trial, researchers from Dana-Farber...
ASCO Announces New Award Honoring Visionary Leader Allen S. Lichter, MD, FASCO
During the 2016 Annual Meeting, ASCO announced the creation of the Allen S. Lichter Visionary Leader Award to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership,...
ASCO 2016: Patients With Cancer With ACA Policies Swiftly Reach Out-of-Pocket Caps
Duke Cancer Institute researchers have found that a hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act...
Enzastaurin Fails to Improve Outcomes in Patients With High-Risk DLBCL in Remission After Chemotherapy
Crump et al found no disease-free survival benefit of maintenance therapy with the selective protein kinase Cb (PKCb) inhibitor enzastaurin in patients with diffuse large B-cell lymphoma (DLBCL) who were in complete remission and at high risk of relapse after first-line chemotherapy, according to a ...
ASCO 2016: Significant Cost Differences Found Among Breast Cancer Chemotherapy Regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences should help guide informed discussions between patients and...
ASCO 2016: Early Detection, Detection of Smaller Cancers Among Benefits of a Primary Care–Based Skin Cancer Screening Program
Skin cancer screenings performed by primary care physicians during routine office visits improve the detection of potentially deadly melanomas and find them in earlier stages, according to new research from the University of Pittsburgh School of Medicine. The results were presented by Ferris et al...
ASCO 2016: Nivolumab Immunotherapy Improves Survival, Quality of Life in Metastatic or Recurrent Head and Neck Cancer
Treatment with nivolumab (Opdivo) doubled overall survival and improved quality of life, with fewer side effects, in a treatment-resistant and rapidly progressing form of head and neck carcinoma, reported a large, randomized international trial co-led by investigators at the University of...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
Prognostic Impact of Recurrence Score and Estrogen Receptor Expression in Breast Cancer After 5 Years of Tamoxifen
As reported in the Journal of Clinical Oncology by Wolmark et al, higher 21-gene recurrence score (RS) was strongly predictive of late disease recurrence among patients with high quantitative estrogen-receptor expression (ESR1) receiving tamoxifen for 5 years in two NRG Oncology/NSABP (National...
Study Finds Apparent Benefit of Adding Fosbretabulin to Bevacizumab in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma
Adding the vascular-disrupting agent fosbretabulin to bevacizumab (Avastin) improved outcomes in patients with recurrent ovarian, tubal, or peritoneal carcinoma, according to a randomized phase II NRG Oncology/Gynecologic Oncology Group study reported in the Journal of Clinical Oncology by Monk et...
ASCO 2016: Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
ASCO 2016: Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery
For breast cancer survivors who carry mutations in BRCA genes, preventive surgery may substantially reduce the risk of future breast and ovarian cancers. However, it appears that black women are far less likely to receive these widely recommended procedures than white or Hispanic...
ASCO 2016: Many Younger Cancer Patients Receive Aggressive End-of-Life Care Despite ASCO’s Choosing Wisely Campaign
An analysis of health claims data from 2007–2014 on more than 28,000 patients under the age of 65 found that a large proportion of patients with advanced solid tumors received at least one form of aggressive care within the last 30 days of life. The study was presented by Chen et al at...
ASCO 2016: Study Finds Use of Mobile Web App Associated With Improved Outcomes in Lung Cancer
A Web-mediated follow-up application (app; Moovcare™) improved advanced lung cancer survival, according to a French multicenter randomized phase III study. Researchers analyzed the association and evolution of self-reported clinical symptoms over time. The median overall survival of patients...
ASCO 2016: Atezolizumab Benefits Patients With Advanced Bladder Cancer
The anti–programmed cell death ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq) is effective in patients with previously untreated advanced bladder cancer who are not eligible for the standard treatment with cisplatin. According to a nonrandomized phase II trial, atezolizumab shrank...
ASCO 2016: Tandem Autologous Stem-Cell Transplant Improves Outcomes for Children With High-Risk Neuroblastoma
Historically, less than 50% of children with high-risk neuroblastoma live 5 or more years after diagnosis. A National Cancer Institute (NCI)-funded phase III trial performed by the Children’s Oncology Group found that adding a second autologous stem-cell transplant to standard therapy...
ASCO 2016: New Antibody-Drug Conjugate Shows Early Promise in Small Cell Lung Cancer
Early findings from a first-in-human clinical trial showed that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) shows promising efficacy against recurrent small cell lung cancer (SCLC). The treatment, which combines a novel anti-DLL3 antibody with a powerful anticancer agent, halted...
ASCO 2016: Temozolomide Chemotherapy Plus Short-Course Radiotherapy Improves Survival in Elderly Patients With Glioblastoma
A Canadian-led randomized phase III trial found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%. These data...
ASCO 2016: 10 Years of Aromatase Inhibitor Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life in Postmenopausal Patients
For updated findings on aromatase inhibitor therapy from the 2016 San Antonio Breast Cancer Symposium, please click here, here, or here. A randomized phase III clinical trial, MA.17R, found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor therapy with...
ASCO 2016: Rucaparib Shows Clinical Benefit in BRCA-Mutated Pancreatic Cancer
The targeted PARP inhibitor rucaparib, which has demonstrated robust clinical activity in patients with ovarian cancer who have a BRCA mutation, also showed promise in previously treated patients with pancreatic cancer who have the mutation, according to results from a phase II clinical study...
ASCO 2016: Maintenance Lenalidomide After Autologous Stem Cell Transplantation Improves Survival in Multiple Myeloma
Several clinical trials have demonstrated that maintenance therapy with lenalidomide (Revlimid) after autologous hematopoietic stem cell transplant reduces the risk of disease progression in patients with multiple myeloma, but there have been no definitive results regarding overall...
ASCO 2016: Locoregional Surgery Followed by Standard Therapy Improves Survival vs Standard Therapy Alone in Stage IV Breast Cancer
Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer followed by standard combination therapies improved survival over standard therapy alone, an international clinical trial revealed. The results of the phase III randomized, controlled trial were presented today...
ASCO 2016: Nivolumab Alone or in Combination With Ipilimumab Active in Recurrent Small Cell Lung Cancer
A study presented by Antonia et al at the 2016 ASCO Annual Meeting (Abstract 100) showed that utilizing the immunotherapeutic agents nivolumab (Opdivo) and ipilimumab (Yervoy) could lead to more effective treatment options for patients with small cell lung cancer (SCLC) who have progressed after...
ASCO 2016: Innovative Direct-to-Patient Outreach May Accelerate Breast Cancer Research
An innovative project launched in October 2015 may help expedite metastatic breast cancer genomics research and provide leads for development of new treatments. In the 7 months since the launch, more than 2,000 patients have enrolled in the research study designed to collect and...
ASCO 2016: Chemotherapy Improves Outcomes for Certain Patients With Anaplastic Glioma
For a more in-depth look at these data, please click here. Patients with anaplastic glioma without 1p/19q codeletion benefit from adjuvant chemotherapy, according to early results from a European phase III trial. The estimated 5-year survival rates were 56% with radiation therapy and...
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
For a more in-depth look at these data, as well as commentary, click here. A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. Adjuvant...
ASCO 2016: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer
A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study. The response rates were comparable among women who received trastuzumab and among...
ASCO 2016: Adding Intraperitoneal Chemotherapy to Intravenous Chemotherapy Slows Ovarian Cancer Progression
For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy intraperitoneally as well as intravenously appears more effective than intravenous chemotherapy alone. For women who were initially treated with chemotherapy prior to surgery, the ...
Statement from FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
“Today, the U.S. Food and Drug Administration (FDA) finalized its efforts to streamline the process used by physicians to request expanded access, often called ‘compassionate use,’ to investigational drugs and biologics for their patients. As a physician, I understand the...
5-Year Results of DASISION Trial of Dasatinib vs Imatinib in CML
As reported in the Journal of Clinical Oncology by Cortes et al, the final 5-year results of the DASISION trial support the safety and efficacy of dasatinib (Sprycel) as first-line treatment in patients with chronic myeloid leukemia (CML) in chronic phase. Initial results in the trial led to...
FDA Approves EGFR Mutation–Detecting Blood Test for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene mutations...
Nearly 20% of Patients With Ovarian Cancer Do Not Undergo Surgery
Nearly 20% of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The findings, which suggest that women may live four times longer with...
ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer
As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic breast cancer. The...
Vulnerable Hospitals, Cancer Surgery Readmissions, and Penalizing Payment Programs
Readmission rates after complex cancer operations tend to be higher in hospitals that are considered to be vulnerable because they serve as safety nets in their communities or have a high number of Medicaid patients. Reasons for higher readmission rates are highly complex and involve socioeconomic...
ASCO Value Framework Update: A Statement by Julie M. Vose, MD, MBA, FASCO
ASCO today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States
A model developed to estimate the absolute risk of breast cancer suggests that a 30-year-old white woman in the United States has an 11.3% risk, on average, of developing invasive breast cancer by the age of 80, according to a new study published by Maas et al in JAMA Oncology. Breast cancer is a...
Early Lapatinib-Related Rash Associated With Improved Outcome in Breast Cancer
An analysis of the phase III adjuvant ALTTO trial showed that early rash was associated with better clinical outcome with lapatinib (Tykerb) treatment of HER2-positive breast cancer, as reported by Sonnenblick et al in the Journal of the National Cancer Institute. It had been previously found that...
Women With New-Onset Atrial Fibrillation May Be at Increased Risk for Malignant Cancer
Among nearly 35,000 initially healthy women who were followed for about 20 years, those with new-onset atrial fibrillation had an increased risk of cancer, according to a study published by Conen et al in JAMA Cardiology. Atrial fibrillation, the most common cardiac arrhythmia, is associated with...
QOPI-Certified Practices Eligible to Receive Discount on Medical Malpractice Rates
ASCO and its wholly owned subsidiary, Quality Oncology Practice Initiative (QOPI®) Certification Program, LLC (QCP), announced May 25 that The Doctors Company, the nation's largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure....
DDW 2016: Low-Residue Diet Prior to Colonoscopy Shows Improved Tolerance and Bowel Preparation vs Clear Liquid Diet
A new study finds that patients who ate certain solid foods, considered “low residue,” were better prepared for their colonoscopies than individuals who followed the conventional liquid diet. Additionally, researchers saw that these patients who ate foods such as eggs, white bread,...
DDW 2016: Endoscopist’s Knowledge of Positive Cologuard Test Improves Colonoscopy Performance
An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation by Johnson et al at Digestive Disease Week (DDW) 2016 (Abstract Su1044). Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the...
New ASCO Cervical Cancer Guidelines Address Global Resource Disparities
On May 25, ASCO issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability. Access to cervical cancer care varies between regions of the...
External Validation of a Prediction Tool for Chemotherapy Toxicity in Older Patients With Cancer
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
Play-Based Procedural Preparation May Aid Children Undergoing Cranial Radiation Therapy
Play-based procedural preparation not only helps children cope with the stress and anxiety of radiation therapy, but can also help reduce the amount of sedation used and cut costs, according to a study from the Child Life Program at St. Jude Children’s Research Hospital. The study was...
Leisure-Time Physical Activity Reduces Risk of Multiple Cancer Types
In a study reported in JAMA Internal Medicine, Moore et al found that greater leisure-time physical activity was associated with a reduced risk for many types of cancer. Study Details The study used pooled data on 1.44 million adults from 12 prospective U.S. and European cohorts with...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
